IBM’s 26% Sell-Off Leaves Investors Pinning Hopes on July 22 Earnings Call

IBM shares fall 26% on Q2 warning, trading near 52-week low with 39% upside to analyst target. Analysts split between buy and reduce; technicals show oversold but not capitulation.

The arithmetic is almost too stark to ignore. With IBM shares closing at €185.72 on Friday, the average analyst price target of €258.80 implies a 39.3 percent upside — one of the widest gaps between market price and Street conviction among large-cap tech names. That chasm encapsulates the central tension gripping the stock: is the market pricing in a permanent impairment, or has the sell-off simply overshot reality?

Investors have been thrown into that debate by a preliminary second-quarter warning that sent the stock crashing 26.30 percent over seven trading sessions, its worst stretch since 1968. Revenue came in at $17.2 billion, up a modest 1 percent but a full $700 million short of expectations. The breakdown told an even more troubling story: software grew 5 percent, consulting stalled, and the infrastructure segment — dominated by mainframes — collapsed 7 percent. Chief executive Arvind Krishna acknowledged the miss bluntly, saying customers were diverting spending away from IBM’s software and infrastructure toward their own AI hardware and memory chips, pushing large deals into the fourth quarter.

The result has left the stock hovering just 4.03 percent above a fresh 52-week low of €178.52, hit on July 16. The technical picture is equally grim: the 14-day relative strength index sits at 31.2, deep in oversold territory but not yet at the extreme sub-30 zone that often signals a capitulation bottom. Shares are trading 18.88 percent below their 50-day moving average and 21.07 percent below the 200-day line, confirming a complete breakdown in medium-term momentum. With annualized volatility at 83.83 percent, the ride is not likely to smooth anytime soon.

Yet the analyst community is far from united in despair. Wedbush’s Dan Ives raised his price target to $350, while Barclays’ Raimo Lenschow initiated coverage at Overweight with the same target. Evercore ISI maintained its Outperform rating at $310, arguing that the revenue shortfall was concentrated in legacy mainframe and select software segments, not a broad-based deterioration. Others have trimmed their estimates but kept buy ratings: Argus cut its target from $360 to $280, and BofA’s Wamsi Mohan lowered his from $330 to $280, citing the unexpectedly large miss and reduced 2026 forecasts.

The bearish camp, however, is growing louder. HSBC analyst Abhishek Shukla downgraded IBM from Hold to Reduce and slashed his price target from $231 to $191, arguing that a synthetic basket of SAP, Accenture, HP and IonQ would replicate IBM’s market exposure at a more attractive valuation. He also questioned the sustainability of IBM’s growth, saying it relies too heavily on ongoing cost cuts rather than organic revenue momentum.

Adding to the pressure, the sharp stock decline has triggered a securities investigation into whether management painted an overly optimistic picture of the deal pipeline. The probe remains open, injecting a fresh layer of legal risk.

Amid that noise, all eyes are fixed on July 22, when IBM will host its full earnings conference call at 5 p.m. Eastern time. The call will include detailed third-quarter guidance, and investors will be listening for two crucial signals: whether the second-quarter headwinds were a one-off timing issue, as management has suggested, or the beginning of a structural shift in enterprise IT budgets toward AI hardware at the expense of software. The internal data already hints at a bifurcation: Red Hat grew 11 percent and distributed infrastructure surged 37 percent, while legacy mainframe business cratered. If Krishna can convince the Street that the delay is temporary and that its software engine remains intact, the gap to the €258.80 target may begin to close quickly.

The alternative scenario is more sobering. If the call suggests that budget reallocation to AI infrastructure will persist for multiple quarters, the stock could retest the €178.52 low — and possibly break lower, given that analysts have already slashed their targets aggressively. IDC analyst Ashish Nadkarni offered a measured take, writing that while Wall Street’s reaction likely overshot, IBM is not immune to the strategic realignment of corporate IT spending, especially if memory-chip shortages continue to fuel the shift.

For now, the chart is acting as if the worst is not yet fully priced in. The July 22 call will either validate that pessimism — or prove that the steep sell-off was nothing more than a deeply oversold mirage.